Department of Neurology and Department of Biomedicine, University Hospital Basel, Petersgraben, Switzerland.
Curr Neurol Neurosci Rep. 2011 Oct;11(5):492-7. doi: 10.1007/s11910-011-0216-9.
The oral sphingosine 1-phosphate receptor (S1PR) modulator fingolimod functionally antagonizes S1PR hereby blocking lymphocyte egress from secondary lymphoid organs to the peripheral blood circulation. This results in a reduction in peripheral lymphocyte counts, including potentially encephalitogenic T cells. In patients with relapsing multiple sclerosis fingolimod has been shown to be an effective treatment. In phase 2 and phase 3 studies fingolimod-treated patients had reduced disease activity clinically and in MRI. Although severe infectious complications occurred in single cases treated with fingolimod, the frequency of overall infections was comparable in fingolimod-treated patients and controls. Overall, in clinical studies fingolimod was well tolerated and had a favorable safety profile. In follow-up studies with continuous fingolimod, treatment showed sustained efficacy while being well tolerated.
口服鞘氨醇 1-磷酸受体（S1PR）调节剂芬戈莫德通过拮抗 S1PR 从而阻止淋巴细胞从次级淋巴器官渗出到外周血液循环。这导致外周淋巴细胞计数减少，包括潜在的致脑炎 T 细胞。在复发型多发性硬化症患者中，芬戈莫德已被证明是一种有效的治疗方法。在 2 期和 3 期研究中，接受芬戈莫德治疗的患者在临床和 MRI 上疾病活动度降低。尽管接受芬戈莫德治疗的个别病例出现了严重的感染并发症，但感染的总发生率在芬戈莫德治疗组和对照组之间无差异。总的来说，在临床研究中，芬戈莫德具有良好的耐受性和有利的安全性特征。在接受连续芬戈莫德治疗的随访研究中，治疗显示出持续的疗效，同时具有良好的耐受性。
